Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (Dextromethorphan and Quinidine) Treatment

Author: Hee Jin CHO ¹ ; Jin Mo PARK ; Jin Sung PARK
Author Information

1. Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, Korea. jinforeva@gmail.com
Publication Type:Case Report
Keywords: Dextromethorphan; Quinidine; Amyotrophic lateral sclerosis
MeSH: Amyotrophic Lateral Sclerosis; Deglutition; Dextromethorphan; Humans; Quinidine; United States Food and Drug Administration
From:Journal of the Korean Neurological Association 2019;37(2):171-173
CountryRepublic of Korea
Language:Korean
Abstract: Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.